ES2685319T3 - Generación de células marcapasos basada en factor de transcripción y métodos de uso de las mismas - Google Patents

Generación de células marcapasos basada en factor de transcripción y métodos de uso de las mismas Download PDF

Info

Publication number
ES2685319T3
ES2685319T3 ES12847179T ES12847179T ES2685319T3 ES 2685319 T3 ES2685319 T3 ES 2685319T3 ES 12847179 T ES12847179 T ES 12847179T ES 12847179 T ES12847179 T ES 12847179T ES 2685319 T3 ES2685319 T3 ES 2685319T3
Authority
ES
Spain
Prior art keywords
generation
methods
transcription factor
cells based
pacemaker cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12847179T
Other languages
English (en)
Inventor
Eduardo Marban
Hee Cheol Cho
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cedars Sinai Medical Center
Original Assignee
Cedars Sinai Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cedars Sinai Medical Center filed Critical Cedars Sinai Medical Center
Application granted granted Critical
Publication of ES2685319T3 publication Critical patent/ES2685319T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/34—Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0657—Cardiomyocytes; Heart cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Developmental Biology & Embryology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Vascular Medicine (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Una composición que comprende Tbxl8 o fragmentos funcionales del mismo capaces de convertir células quiescentes o células madre en células marcapasos para su uso como medicamento para tratar a un sujeto afectado con una afección seleccionada del grupo que consiste en arritmia cardíaca, síndrome del seno enfermo, bloqueo AV, bradicardia, taquicardia o insuficiencia cardíaca.
ES12847179T 2011-11-09 2012-11-08 Generación de células marcapasos basada en factor de transcripción y métodos de uso de las mismas Active ES2685319T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161557812P 2011-11-09 2011-11-09
PCT/US2012/064204 WO2013070952A1 (en) 2011-11-09 2012-11-08 Transcription factor-based generation of pacemaker cells and methods of using same

Publications (1)

Publication Number Publication Date
ES2685319T3 true ES2685319T3 (es) 2018-10-08

Family

ID=48290559

Family Applications (1)

Application Number Title Priority Date Filing Date
ES12847179T Active ES2685319T3 (es) 2011-11-09 2012-11-08 Generación de células marcapasos basada en factor de transcripción y métodos de uso de las mismas

Country Status (5)

Country Link
US (3) US9763999B2 (es)
EP (2) EP3446716B1 (es)
JP (3) JP6236393B2 (es)
ES (1) ES2685319T3 (es)
WO (1) WO2013070952A1 (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10973876B2 (en) 2011-11-09 2021-04-13 Cedars-Sinai Medical Center Transcription factor-based generation of pacemaker cells and methods of using same

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102013114671B4 (de) 2013-12-20 2015-10-29 Universität Rostock Verfahren zur Erzeugung von Sinusknotenzellen ("Herz-Schrittmacherzellen") aus Stammzellen
US9913865B2 (en) * 2015-12-28 2018-03-13 Ingeneron Inc. Induced pacemaker and Purkinje cells from adult stem cells
US11164596B2 (en) 2016-02-25 2021-11-02 Samsung Electronics Co., Ltd. Sensor assisted evaluation of health and rehabilitation
US10172517B2 (en) 2016-02-25 2019-01-08 Samsung Electronics Co., Ltd Image-analysis for assessing heart failure
US10362998B2 (en) 2016-02-25 2019-07-30 Samsung Electronics Co., Ltd. Sensor-based detection of changes in health and ventilation threshold
US10420514B2 (en) 2016-02-25 2019-09-24 Samsung Electronics Co., Ltd. Detection of chronotropic incompetence
WO2017192602A1 (en) 2016-05-02 2017-11-09 Emory University Uses of epithelial-to-mesenchymal inhibitors in generating pacemaker cells
GB2571704A (en) * 2018-02-22 2019-09-11 Georg August Univ Gottingen Stiftung Offentlichen Rechts Univer Sitatsmedzin Goettingen Prevention or treatment of cardiac arrhytmia and sudden cardiac death
WO2019169228A1 (en) * 2018-03-01 2019-09-06 Georgia Tech Research Corporation Methods and compositions for mrna-based modulation and detection of cell phenotypes
DE102018212005B4 (de) 2018-07-18 2020-08-06 Universität Rostock Herzschrittmacherzellen auf Chip zur Etablierung eines autonom regulierbaren elektrischen Schrittmachers
CN113801842A (zh) * 2021-09-18 2021-12-17 江苏省苏北人民医院 一种促进胚胎样干细胞向起搏样干细胞分化方法
WO2024020587A2 (en) 2022-07-22 2024-01-25 Tome Biosciences, Inc. Pleiopluripotent stem cell programmable gene insertion

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5660038A (en) 1980-10-20 1981-05-23 Nec Corp Semiconductor device
WO1997045550A2 (en) 1996-05-31 1997-12-04 Baxter International Inc. Mini-adenoviral vector
US20020106729A1 (en) 2000-07-03 2002-08-08 Bleck Gregory T. Expression vectors
IL158618A0 (en) * 2001-04-27 2004-05-12 Univ Johns Hopkins Biological pacemaker
US20050123898A1 (en) * 2001-07-18 2005-06-09 Moritz Hillgenberg System for producing clonal or complex populations of recombinant adenoviruses, and the application of the same
US20040214182A1 (en) * 2003-04-25 2004-10-28 Vinod Sharma Genetic modification of targeted regions of the cardiac conduction system
EP1931783A1 (en) 2005-09-09 2008-06-18 The Trustees of Columbia University in the City of New York Chimeric hcn channels
JP4595786B2 (ja) * 2005-11-01 2010-12-08 セイコーエプソン株式会社 印刷装置
US7787949B2 (en) 2006-10-30 2010-08-31 Medtronic, Inc. Biological pacemaker compositions and systems incorporating interstitial cells of Cajal
US8076305B2 (en) * 2006-11-30 2011-12-13 Medtronic, Inc. Biological pacemakers including mutated hyperpolarization-activated cyclic nucleotide-gated (HCN) channels
US20100172883A1 (en) * 2007-01-19 2010-07-08 Bruneau Benoit Gaetan Methods of generating cardiomyocytes
US20090233990A1 (en) * 2007-11-01 2009-09-17 Hee Cheol Cho Generation of biological pacemaker activity
US20100285580A1 (en) * 2007-11-15 2010-11-11 Sylvia Evans Cardiac Conduction System (CCS) Progenitor Cells and Uses Thereof
WO2010059806A2 (en) * 2008-11-20 2010-05-27 Cedars-Sinai Medical Center Generation of induced pluripotent stem cells without the use of viral vectors
WO2010108126A2 (en) * 2009-03-19 2010-09-23 Fate Therapeutics, Inc. Reprogramming compositions and methods of using the same
US9517250B2 (en) * 2010-04-28 2016-12-13 The J. David Gladstone Institutes Methods for generating cardiomyocytes
US9017661B2 (en) * 2011-02-22 2015-04-28 The Board Of Regents Of The University Of Texas System Cardiac repair by reprogramming of cardiac fibroblasts into cardiomyocytes
EP3446716B1 (en) 2011-11-09 2020-03-18 Cedars-Sinai Medical Center Transcription factor-based generation of pacemaker cells and methods of using same

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10973876B2 (en) 2011-11-09 2021-04-13 Cedars-Sinai Medical Center Transcription factor-based generation of pacemaker cells and methods of using same

Also Published As

Publication number Publication date
JP2018019718A (ja) 2018-02-08
EP3446716A1 (en) 2019-02-27
EP2776071B1 (en) 2018-08-08
JP6236393B2 (ja) 2017-11-22
US20180071364A1 (en) 2018-03-15
WO2013070952A1 (en) 2013-05-16
US20210260158A1 (en) 2021-08-26
JP6584475B2 (ja) 2019-10-02
US10973876B2 (en) 2021-04-13
JP2019218394A (ja) 2019-12-26
JP2014532767A (ja) 2014-12-08
EP2776071A1 (en) 2014-09-17
EP2776071A4 (en) 2015-07-29
US20150359845A1 (en) 2015-12-17
EP3446716B1 (en) 2020-03-18
US9763999B2 (en) 2017-09-19

Similar Documents

Publication Publication Date Title
ES2685319T3 (es) Generación de células marcapasos basada en factor de transcripción y métodos de uso de las mismas
IN2014DN09782A (es)
PE20150223A1 (es) Anticuerpos antagonistas mejorados contra factor-8 de crecimiento y diferenciacion y usos de los mismos
PH12015502042A1 (en) Use of linagliptin in cardio-and renoprotective antidiabetic therapy
AR093386A1 (es) Composicion para tratar la diabetes o la diabesidad que comprende un analogo de oxintomodulina y metodo de tratamiento
UY33776A (es) Ácidos 1-bencilcicloalquilcarboxílicos sustituidos y su uso
CO7240369A2 (es) Ácido 5-aminotetrahidroquinolin-2-carboxílicos novedosos y su uso
BR112015011933A2 (pt) composições bacterianas sinérgicas e métodos de produção e uso das mesmas
BR112016025331A2 (pt) composições antimicrobianas
SG10201809290SA (en) Compositions and Methods to Treating Hemoglobinopathies
WO2014144932A3 (en) Methods of using zscan4 for rejuvenating human cells
MX350282B (es) Molecula de union que tiene actividad neutralizadora del virus de la influenza a, producida a partir de celulas b humanas.
WO2013177535A8 (en) Methods of treating a metabolic syndrome by modulating heat shock protein (hsp) 90-beta
BR112018000756A2 (pt) catalisador multimetálico que contém cobre, uso do catalisador, e método para usar um catalisador
CO6410278A2 (es) Disoluciones pediátricas que continen un beta-bloqueante
GT201200345A (es) Compuestos heterocìclicos, su preparaciòn y su aplicaciòn terapèutica
CL2013000735A1 (es) Uso de una composicion que comprende compuestos derivados de 1-h-imidazol-4-il sustituido para el tratamiento de enfermedades y condiciones de la piel, tales como rosacea, daño solar cronico, psoriasis, entre otras; kit farmaceutico.
AR085616A1 (es) Composicion farmaceutica inhalable que comprende glicopirrolato, uso
CR11631A (es) Paramyxovirus eficaz como antitumoral
WO2013109055A3 (ko) 개 유래의 자연살해세포 및 이의 대량 증식방법
BR112015010225A2 (pt) compostos tricíclicos e seus métodos de produção e utilização
AR088850A1 (es) Catalizador de hidropirolisis y proceso de conversion de biomasa
WO2014165723A3 (en) Enhanced osteogenic activity of daidzein analogs on human mesenchymal stem cells
EP2600873A4 (en) PHARMACEUTICAL COMPOSITIONS FOR TERMINATING ACUTE CARDIAC ERRORS, FOR RECOVERING THE SINUS RTHYTHMUS, FOR PREVENTING THE RETROSPECTIVE OF CARDIAC ERRORS AND / OR FOR MAINTAINING THE NORMAL SINUS RYTHMTH IN MAMMALS
CO6430497A2 (es) Metodo o sistema que usa biomarcadores para el seguimiento de un tratamiento